{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:39Z","timestamp":1786997859983,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T02:40:24Z","timestamp":1649385624000},"page":"3072-3084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine"],"prefix":"10.1016","volume":"40","author":[{"given":"Helen J.","family":"Mayfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen L.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Litt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aapeli","family":"Vuorinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty R.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Mengersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.vaccine.2022.04.004_b0005","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.004_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5694\/mja2.51136","article-title":"Communicating with patients and the public about COVID-19 vaccine safety: recommendations from the Collaboration on Social Science and Immunisation","volume":"215","author":"Leask","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2022.04.004_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.07.013","article-title":"Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia","author":"MacIntyre","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.004_b0020","series-title":"Risk assessment and decision analysis with Bayesian networks","author":"Fenton","year":"2013"},{"key":"10.1016\/j.vaccine.2022.04.004_b0025","article-title":"A Bayesian network model for personalised COVID19 risk assessment and contact tracing","author":"Fenton","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2022.04.004_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecolmodel.2017.05.011","article-title":"Common quandaries and their practical solutions in Bayesian network modeling","volume":"358","author":"Marcot","year":"2017","journal-title":"Ecol Model"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2022.04.004_b0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ecolmodel.2006.11.033","article-title":"Advantages and challenges of Bayesian networks in environmental modelling","volume":"203","author":"Uusitalo","year":"2007","journal-title":"Ecol Model"},{"key":"10.1016\/j.vaccine.2022.04.004_b0040","unstructured":"McLachlan S, Lucas PJ, Dube K, Hitman G, Osman M, Kyrimi E., et al. The fundamental limitations of COVID-19 contact tracing methods and how to resolve them with a Bayesian network approach; 2020."},{"key":"10.1016\/j.vaccine.2022.04.004_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268821001357","article-title":"Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling","volume":"149","author":"Wu","year":"2021","journal-title":"Epidemiol Infect"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2022.04.004_b0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/13669877.2020.1778771","article-title":"Bayesian network analysis of Covid-19 data reveals higher infection prevalence rates and lower fatality rates than widely reported","volume":"23","author":"Neil","year":"2020","journal-title":"J Risk Res"},{"key":"10.1016\/j.vaccine.2022.04.004_b0055","unstructured":"Immunisation Coalition. CoRiCal: Covid Risk Calculator. 2021 24 October 2021]; Available from: https:\/\/corical.immunisationcoalition.org.au."},{"key":"10.1016\/j.vaccine.2022.04.004_b0060","article-title":"Quantifying the risks versus benefits of the Pfizer COVID-19 vaccine in Australia: a Bayesian network analysis","author":"Sinclair","year":"2022","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.004_b0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.envsoft.2010.03.032","article-title":"Using Bayesian Networks to complement conventional analyses to explore landholder management of native vegetation","volume":"26","author":"Ticehurst","year":"2011","journal-title":"Environ Modell Software"},{"key":"10.1016\/j.vaccine.2022.04.004_b0070","unstructured":"Bayes Fusion. GeNIe Modeller available at https:\/\/www.bayesfusion.com\/. 2019."},{"key":"10.1016\/j.vaccine.2022.04.004_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2016.02.024","article-title":"Survival after splanchnic vein thrombosis: A 20-year nationwide cohort study","volume":"141","author":"S\u00f8gaard","year":"2016","journal-title":"Thromb Res"},{"issue":"04","key":"10.1016\/j.vaccine.2022.04.004_b0080","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","article-title":"Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome","volume":"117","author":"Ageno","year":"2017","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.004_b0085","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1161\/STROKEAHA.120.030800","article-title":"Incidence and mortality of cerebral venous thrombosis in a norwegian population","volume":"51","author":"Kristoffersen","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.vaccine.2022.04.004_b0090","first-page":"1","article-title":"Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases","volume":"39","author":"Taquet","year":"2021","journal-title":"Emedicine"},{"key":"10.1016\/j.vaccine.2022.04.004_b0095","unstructured":"ATAGI Australian Technical Advisory Group on Immunisation (ATAGI) weekly COVID-19 meeting on 8 September 2021 update; 2021."},{"key":"10.1016\/j.vaccine.2022.04.004_b0100","unstructured":"NSW Government NSW COVID-19 cases data; 2021."},{"key":"10.1016\/j.vaccine.2022.04.004_b0105","unstructured":"NNDSS National Notifiable Diseases Surveillance System public datasets; 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.004_b0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.eswa.2012.07.026","article-title":"A proposed validation framework for expert elicited Bayesian Networks","volume":"40","author":"Pitchforth","year":"2013","journal-title":"Expert Syst Appl"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.004_b0115","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-92","article-title":"A tutorial on sensitivity analyses in clinical trials: the what, why, when and how","volume":"13","author":"Thabane","year":"2013","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.vaccine.2022.04.004_b0120","unstructured":"Doherty Institute, Doherty modelling report revised 10th August 2021; 2021, Doherty Institute. p. Table S2.5."},{"key":"10.1016\/j.vaccine.2022.04.004_b0125","unstructured":"Vaccine Effectiveness Expert Panel VEEP: Vaccine effectiveness table; 16 July 2021. 2021."},{"key":"10.1016\/j.vaccine.2022.04.004_b0130","unstructured":"ATAGI, T. Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca; 2021."},{"key":"10.1016\/j.vaccine.2022.04.004_b0135","unstructured":"Australian Bureau of Statistics. Data downloads - time series spreadsheets. National, state and territory population, 2021. 2021 01\/10\/2021]; Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/dec-2020#data-download."},{"key":"10.1016\/j.vaccine.2022.04.004_b0140","unstructured":"Bayes Fusion. Sensitivity analysis in Bayesian networks (and influence diagrams). 2020 [cited 2022 28\/03\/22]; Available from: https:\/\/support.bayesfusion.com\/docs\/GeNIe\/bn_sensitivitybn.html."},{"key":"10.1016\/j.vaccine.2022.04.004_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.10.079","article-title":"Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework","author":"Lau","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.004_b0150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.envsoft.2012.07.008","article-title":"Bayesian belief modeling of climate change impacts for informing regional adaptation options","volume":"44","author":"Richards","year":"2013","journal-title":"Environ Modell Software"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:37:08Z","timestamp":1718422628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22004182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22004182"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.004","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.28.21265588","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}